ea0098t2 | Trials In Progress | NANETS2023
Demeure, MD Michael J.
, Cohn, MD Allen L.
, Seery, MD Tara
, Ding, MS, MA Li
, Aziz, MD Usman
, Navarro, MD Willis
, Paulson, MD Scott
Background: Neuroendocrine tumors (NETs; ~2% of all malignancies) commonly arise from the GI tract, pancreas, and lung and often present with metastatic disease. The PI3K/Akt/mTOR pathway is implicated in the pathogenesis and progression of NETs. The oral mTOR inhibitor (mTORi), everolimus, is approved for treatment of patients with NETs of the GI tract, lung, or pancreas. However, due to the rarity and heterogeneity, nonspecific clinical symptoms, and unique indolent biology,...